Vestal Point Capital LP Has $10.47 Million Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Vestal Point Capital LP lessened its holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 41.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,025,000 shares of the company's stock after selling 725,000 shares during the quarter. Vestal Point Capital LP owned approximately 2.81% of iTeos Therapeutics worth $10,465,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of iTeos Therapeutics by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 1,500,602 shares of the company's stock valued at $20,468,000 after buying an additional 9,660 shares during the last quarter. Public Employees Retirement System of Ohio grew its holdings in shares of iTeos Therapeutics by 4.9% during the first quarter. Public Employees Retirement System of Ohio now owns 39,003 shares of the company's stock valued at $532,000 after purchasing an additional 1,817 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of iTeos Therapeutics by 4.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 121,250 shares of the company's stock worth $1,799,000 after purchasing an additional 5,409 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of iTeos Therapeutics by 35.9% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,998 shares of the company's stock worth $178,000 after purchasing an additional 3,172 shares during the last quarter. Finally, Panagora Asset Management Inc. boosted its position in iTeos Therapeutics by 8.9% during the 2nd quarter. Panagora Asset Management Inc. now owns 131,553 shares of the company's stock valued at $1,952,000 after purchasing an additional 10,787 shares during the period. Institutional investors own 97.16% of the company's stock.

Insider Transactions at iTeos Therapeutics

In other news, CFO Matthew Gall acquired 5,000 shares of the stock in a transaction on Tuesday, November 19th. The shares were purchased at an average cost of $7.73 per share, for a total transaction of $38,650.00. Following the transaction, the chief financial officer now owns 65,429 shares in the company, valued at approximately $505,766.17. This trade represents a 8.27 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 12.50% of the stock is owned by insiders.

iTeos Therapeutics Price Performance

Shares of iTeos Therapeutics stock traded up $0.01 on Friday, hitting $8.55. The company had a trading volume of 125,012 shares, compared to its average volume of 444,936. iTeos Therapeutics, Inc. has a 52 week low of $7.54 and a 52 week high of $18.75. The company has a market cap of $312.33 million, a PE ratio of -2.71 and a beta of 1.39. The business has a 50-day simple moving average of $9.18 and a 200-day simple moving average of $13.70.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share for the quarter, topping analysts' consensus estimates of ($1.18) by $0.13. On average, equities research analysts predict that iTeos Therapeutics, Inc. will post -3.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ITOS has been the topic of several recent research reports. HC Wainwright reiterated a "buy" rating and issued a $46.00 price objective on shares of iTeos Therapeutics in a research report on Friday, November 15th. Wells Fargo & Company initiated coverage on iTeos Therapeutics in a research report on Tuesday, August 13th. They set an "overweight" rating and a $31.00 price objective for the company. Wedbush reissued an "outperform" rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a report on Tuesday, November 12th. Finally, JPMorgan Chase & Co. cut their target price on iTeos Therapeutics from $27.00 to $24.00 and set an "overweight" rating on the stock in a research note on Monday, August 12th.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.